MOG (35-55): Gold-Standard Peptide for Experimental Autoimmune Encephalomyelitis Modeling

Executive Summary: MOG (35-55) is a truncated peptide from human myelin oligodendrocyte glycoprotein, commonly used to induce experimental autoimmune encephalomyelitis (EAE), the leading animal model for multiple sclerosis (MS) research (APExBIO). It reliably elicits robust T and B cell immune responses and recapitulates key neuroinflammatory and demyelinating features of MS (Xu et al., 2025). In vivo, subcutaneous administration induces dose-dependent MS-like symptoms and weight loss in mice. The peptide increases NADPH oxidase and MMP-9 activities, offering insights into oxidative stress and extracellular matrix remodeling. APExBIO’s MOG (35-55) (SKU A8306) is a reproducible, mechanistically validated reagent for autoimmune encephalomyelitis studies (Immuneland).

Biological Rationale

MOG (35-55) is a peptide fragment corresponding to amino acids 35–55 of the human myelin oligodendrocyte glycoprotein (MOG), a CNS-specific member of the immunoglobulin superfamily (Xu et al., 2025). MOG is highly immunogenic and a principal target of the autoimmune response in MS. The peptide is widely adopted for inducing EAE in rodents, mirroring critical hallmarks of MS, including demyelination, neuroinflammation, and relapsing-remitting neurological deficits (ku55933.com). Its use has enabled detailed mechanistic studies on immune pathways, including T and B cell activation, antigen presentation, and the molecular underpinnings of autoimmunity.

Mechanism of Action of MOG (35-55)

MOG (35-55) acts as an immunodominant peptide, recognized by both CD4+ T cells and B cells in susceptible rodent strains. Upon administration—typically emulsified in complete Freund's adjuvant (CFA)—it triggers a cascade of immune responses:

• T cell activation: CD4+ T cells recognize MOG (35-55) presented via MHC class II, leading to cytokine secretion (e.g., IFN-γ, IL-17) and neuroinflammatory infiltration.
• B cell response: B cells generate anti-MOG autoantibodies, contributing to demyelination and lesion formation.
• Neuroinflammation: The immune response targets myelin, resulting in plaque-like demyelination and neurological deficits.
• Induction of oxidative stress: In vitro, MOG (35-55) increases NADPH oxidase and MMP-9 activities in immune and glial cells, linking it to oxidative damage and matrix remodeling (Xu et al., 2025).
• STAT1/STAT2 regulation: PARP7 inhibition stabilizes STAT1/STAT2, which relieves EAE symptoms, establishing the model's utility for dissecting interferon signaling (Xu et al., 2025).

Evidence & Benchmarks

• MOG (35-55) (A8306) induces chronic, relapsing-remitting EAE in C57BL/6 and HLA-DR2-transgenic mice when administered subcutaneously at 50–150 μg per animal, with severity increasing dose-dependently (APExBIO).
• MOG (35-55) elicits robust T and B cell immune responses, leading to extensive CNS demyelination and perivascular infiltration (Immuneland).
• In vitro, the peptide increases NADPH oxidase and MMP-9 activities, linking it to oxidative stress and ECM remodeling pathways (Xu et al., 2025).
• PARP7 inhibition in the MOG (35-55) EAE model stabilizes STAT1/STAT2, relieves EAE symptoms, and highlights the model's translational value for MS therapy research (Xu et al., 2025).
• Stock solutions of MOG (35-55) are stable at -20°C when desiccated and show maximal solubility at ≥32.25 mg/mL in water and ≥86 mg/mL in DMSO; the peptide is insoluble in ethanol (APExBIO).

This article extends the discussion in 'MOG (35-55): Gold Standard Peptide for Experimental Autoi...' by providing new mechanistic insights into oxidative stress modulation and STAT1/STAT2 regulation in EAE models.

Applications, Limits & Misconceptions

Key Applications:

• Modeling relapsing-remitting and chronic progressive forms of MS in rodents.
• Studying T and B cell-mediated autoimmunity and neuroinflammation.
• Assessing new immunomodulatory therapies in preclinical MS models.
• Investigating molecular pathways such as NADPH oxidase and MMP-9 in demyelination.
• Dissecting type I interferon signaling via PARP7/STAT1/STAT2 axes (Xu et al., 2025).

For additional practical guidance, see 'Reliable EAE Induction: Scenario-Driven Use of MOG (35-55)...', which this article updates with recent data on molecular endpoints and peptide stability.

Common Pitfalls or Misconceptions

• MOG (35-55) is not a direct model for progressive MS subtypes: It primarily recapitulates relapsing-remitting forms.
• Peptide solubility issues: The peptide is insoluble in ethanol; improper preparation can result in aggregation and poor EAE induction (APExBIO).
• Species/strain variability: Not all mouse strains are equally susceptible; selection must align with research goals (Immuneland).
• Does not recapitulate all MS pathologies: MOG (35-55)-induced EAE lacks full spectrum of human MS features (e.g., cortical demyelination, B cell follicle formation).
• Batch preparation errors: Inadequate warming or ultrasonic bath treatment may lower yield and reproducibility.

Workflow Integration & Parameters

For consistent results, dissolve MOG (35-55) in sterile water at 0.50 mg/mL, using warming and ultrasonic bath treatment to enhance solubility (APExBIO). Prepare stock solutions fresh, store desiccated at -20°C, and avoid repeated freeze-thaw cycles. For EAE induction, emulsify peptide with CFA; administer 50–150 μg subcutaneously in rodents, adjusting dose for strain sensitivity. Evaluate disease progression using clinical scoring, weight monitoring, and histopathology. For in vitro assays, titrate concentrations to evaluate dose-dependent effects on immune cell activation, NADPH oxidase, and MMP-9 activity. For advanced troubleshooting and protocol optimization, see 'MOG (35-55): Optimizing Experimental Autoimmune Encephalo...'; this article adds updated stability and molecular endpoint data.

Conclusion & Outlook

MOG (35-55) remains the gold-standard peptide for inducing EAE, supporting robust, reproducible modeling of autoimmune neuroinflammation. Its validated use in rodent models underpins translational MS research, enabling mechanistic dissection of immune pathways and therapeutic testing. Recent advances—such as insights into PARP7/STAT1/STAT2 regulation—underscore the evolving utility of this model (Xu et al., 2025). As new therapeutic strategies target immune modulation and neuroprotection, APExBIO’s MOG (35-55) provides a critical, well-characterized tool for preclinical discovery.